Skip to main content

Foresite Capital Management IV, LLC

13F filer · CIK 0001704132
Reported Aug 14, 2026
Net buyer this quarter
13F portfolio value$290MU.S. long equity reported on 13F
Positions61 new · 3 closed
Net flow last quarter+$4.56MBuys minus sells
Top 10 positions weight100.0%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 20266 positions
PHVSPharvaris N.V.$165M56.95%7.33%Not reportedQ1 2021
CYTKCytokinetics Inc$60.9M20.98%0.57%+42.0%Q4 2018
EIKNEikon Therapeutics, Inc.$25.4M8.74%3.59%Not reportedQ1 2026
RLAYRelay Therapeutics, Inc.$23.4M8.06%0.57%+25.0%Q3 2020
XENEXenon Pharmaceuticals Inc.$9.66M3.33%0.17%Not reportedQ3 2018
CRNXCrinetics Pharmaceuticals, Inc.$5.61M1.93%0.14%Not reportedQ3 2018
Q1 2026Reported May 15, 20268 positions
PHVSPharvaris N.V.$135M56.94%7.33%Not reportedQ1 2021
CYTKCytokinetics Inc$33.2M13.99%0.41%+9.8%Q4 2018
EIKNEikon Therapeutics, Inc.$20.6M8.67%3.59%NewQ1 2026
LYELLyell Immunopharma, Inc.$16.1M6.77%3.43%Not reportedQ2 2021
RLAYRelay Therapeutics, Inc.$9.95M4.20%0.53%Not reportedQ3 2020
XENEXenon Pharmaceuticals Inc.$9.3M3.92%0.17%Not reportedQ3 2018
ALECAlector, Inc.$8.36M3.53%3.50%Not reportedQ1 2019
MAZEMaze Therapeutics, Inc.$4.68M1.98%0.32%-70.0%Q1 2025
Q4 2025Reported Feb 17, 20267 positions
PHVSPharvaris N.V.$133M57.73%7.33%Not reportedQ1 2021
CYTKCytokinetics Inc$29.1M12.68%0.37%Not reportedQ4 2018
LYELLyell Immunopharma, Inc.$24.6M10.72%3.77%Not reportedQ2 2021
MAZEMaze Therapeutics, Inc.$21.7M9.43%1.06%Not reportedQ1 2025
RLAYRelay Therapeutics, Inc.$8.46M3.68%0.58%Not reportedQ3 2020
XENEXenon Pharmaceuticals Inc.$7.17M3.12%0.20%Not reportedQ3 2018
ALECAlector, Inc.$6.06M2.64%3.52%Not reportedQ1 2019
Q3 2025Reported Nov 14, 20256 positions
PHVSPharvaris N.V.$119M65.29%8.79%+8.3%Q1 2021
CYTKCytokinetics Inc$25.2M13.79%0.38%Not reportedQ4 2018
MAZEMaze Therapeutics, Inc.$13.6M7.42%1.09%-75.3%Q1 2025
LYELLyell Immunopharma, Inc.$13M7.12%4.15%Not reportedQ2 2021
XENEXenon Pharmaceuticals Inc.$6.42M3.52%0.21%Not reportedQ3 2018
RLAYRelay Therapeutics, Inc.$5.22M2.86%0.58%Not reportedQ3 2020
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.